



ASX ANNOUNCEMENT

**New Appointments
Strengthen Product Commercialisation**

*Dr Paul MacLeman appointed to new Chief Operating Officer position
Dr Peter Claxton appointed to new position as Regulatory Affairs Consultant*

8 November 2004, Sydney: Imugene (ASX: IMU) has appointed **Dr Paul MacLeman** to the new senior position of Chief Operating Officer.

Most recently Dr MacLeman was head of Agenix's global animal health business. During his Agenix tenure Dr MacLeman re-structured and re-focused the business by expanding the Agenix animal health team and re-structured the US & EU product channels by sourcing and implementing new multi-national distributor agreements. Results included significant sales increases with improved margins.

This appointment is vital for the rollout of Imugene's animal health products across world markets. Imugene will sell certain products direct to users and will use intermediary distributors for its other animal health products.

Commenting on the appointment, Imugene Executive Chairman, Graham Dowland stated "Dr MacLeman has over 15 years commercial experience in the animal health and biotechnology industry, having successfully taken biological products from the laboratory, through regulatory, manufacturing, marketing and launch. This appointment is extremely timely for Imugene and Dr MacLeman is a very welcome addition to the Imugene team."

Dr MacLeman is a qualified veterinarian and has completed an MBA.

Imugene has also appointed **Dr Peter Claxton** as Regulatory Affairs Consultant to oversee the regulatory process for both the Adenoviral Vector based vaccines and the Receptor Mimic Technology product range.

For the past eight years Dr Claxton has been consulting to the veterinary biologicals and pharmaceuticals industries. His strengths include R&D programs that comply with regulatory requirements, product development, technology transfer, manufacture, quality assurance and product licensing, GMP and QA auditing for companies producing veterinary vaccines (viral, bacterial, protozoal).

ABN: 99 009 179 551

Level 1, 14 – 20 Delhi Road, North Ryde NSW 2113

PO Box 307, North Ryde NSW 1870

Tel: +61 2 9870 7330 Fax: +61 2 9888 9338

website: www.imugene.com

For over 10 years prior to consulting, Dr Claxton was technical director of Arthur Webster Pty Ltd and responsible for in-house R&D for vaccines for poultry, companion animals and grazing animals. Dr Claxton is also a qualified veterinarian, with a PhD in Veterinary Science and a Postgraduate Diploma in Bacteriology from London University.

“Dr Claxton has over 30 years relevant experience in the animal health product registration and regulatory environment in Australia and internationally. Dr Claxton’s appointment together with Dr MacLeman’s provides Imugene with the resources to implement its product development and commercialisation strategies as planned. These two appointments will add to the impetus already achieved with the development and commercialisation of our product range,” said Mr Dowland.

END

More information:

***Dr Warwick Lamb,
Imugene’s Managing Director
+61 2 9870 7330***

***Mr Graham Dowland,
Imugene’s Executive Chairman
+61 8 9322 9189***

***Mr Rudi Michelson
Monsoon Communications
+61 3 9620 3333***

ABOUT IMUGENE:

Imugene specialises in commercialising animal health products for production animals and pets.

Imugene’s products safely prevent disease and reduce or eliminate antibiotics and harmful chemicals in animals. Animal antibiotics and chemicals in the human food chain have been linked to the emergence of dangerous resistant bacteria in people and food residues.

Imugene owns the worldwide rights to two platform technologies. The ***Receptor Mimic Technology*** for gastrointestinal diseases of pigs and potentially all other animal species. Secondly, the ***Adenoviral Vector Delivery System*** for pigs and poultry delivers Imugene’s highly effective *poultry productivity enhancer*.

Imugene’s poultry and pig portfolio is targeting a worldwide US\$3 billion annual market and replace existing chemical and antibiotic products. Consumer demands for residue free food and health regulatory pressures will bolster Imugene’s prospects.

Visit the Imugene Website: www.imugene.com

ABN: 99 009 179 551
 Level 1, 14 – 20 Delhi Road, North Ryde NSW 2113
 PO Box 307, North Ryde NSW 1870
 Tel: +61 2 9870 7330 Fax: +61 2 9888 9338
 website: www.imugene.com